STAT3 signaling is activated preferentially in tumor-initiating cells in claudin-low models of human breast cancer

Stem Cells

Volumn 32, Issue 10, 2014, Pages 2571-2582

  Wei, Wei ^a   Tweardy, David J ^a   Zhang, Mei ^b   Zhang, Xiaomei ^a   Landua, John ^a   Petrovic, Ivana ^a   Bu, Wen ^a   Roarty, Kevin ^a   Hilsenbeck, Susan G ^a   Rosen, Jeffrey M ^a   Lewis, Michael T ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer stem cells; Cell signaling; Drug target; Experimental models; Fluorescence activated cell sorting; Fluorescent protein reporter genes; Lentiviral vector; Signal transducer and activator of transcription

Indexed keywords

CLAUDIN; ENHANCED GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; STAT3 PROTEIN; GREEN FLUORESCENT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER STEM CELL; CELL SUBPOPULATION; CONTROLLED STUDY; ENRICHMENT CULTURE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PROTEIN LOCALIZATION; TUMOR INITIATING CELL; TUMOR XENOGRAFT; ANIMAL; BIOLOGICAL MODEL; BREAST TUMOR; CARCINOGENESIS; DRUG SCREENING; FLUORESCENCE; LENTIVIRINAE; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; REPORTER GENE; REPRODUCIBILITY; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CARCINOGENESIS; CELL LINE, TUMOR; CLAUDINS; FEMALE; FLUORESCENCE; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HUMANS; LENTIVIRUS; MICE, SCID; MODELS, BIOLOGICAL; NEOPLASTIC STEM CELLS; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; STAT3 TRANSCRIPTION FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84906219403     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1752     Document Type: Article

References (63)

1. Stebbing J, Ellis P. An overview of drug development for metastatic breast cancer. Br J Nurs 2012;21:S18-22.
2. Warner E. Clinical practice. Breast-cancer screening. N Engl J Med 2011;365:1025-1032.
3. Li X, Lewis MT, Huang J et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008; 100:672-679.
4. Zhang M, Atkinson RL, Rosen JM. Selective targeting of radiation-resistant tumor-initiating cells. Proc Natl Acad Sci USA 2010; 107:3522-3527.
5. Visvader JE. Cells of origin in cancer. Nature 2011;469:314-322.
6. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-768.
7. Rosen JM, Jordan CT. The increasing complexity of the cancer stem cell paradigm. Science 2009;324:1670-1673.
8. Garvalov B, Acker T. Cancer stem cells: A new framework for the design of tumor therapies. J Mol Med 2011;89:95-107.
9. Tang DG. Understanding cancer stem cell heterogeneity and plasticity. Cell Res 2012;22:457-472.
10. Herschkowitz J, Simin K, Weigman V et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007;8:R76.
11. Chatterjee-Kishore M, van den Akker F, Stark GR. Association of STATs with relatives and friends. Trends Cell Biol 2000;10:106-111.
12. Raz R, Lee CK, Cannizzaro LA et al. Essential role of STAT3 for embryonic stem cell pluripotency. Proc Natl Acad Sci USA 1999;96:2846-2851.
13. Matsuda T, Nakamura T, Nakao K et al. STAT3 activation is sufficient to maintain an undifferentiated state of mouse embryonic stem cells. EMBO J 1999;18:4261-4269.
14. Cartwright P, McLean C, Sheppard A et al. LIF/STAT3 controls ES cell self-renewal and pluripotency by a Myc-dependent mechanism. Development 2005;132:885-896.
15. Torres J, Watt FM. Nanog maintains pluripotency of mouse embryonic stem cells by inhibiting NFkappaB and cooperating with Stat3. Nat Cell Biol 2008;10:194-201.
16. Bromberg JF, Wrzeszczynska MH, Devgan G et al. Stat3 as an oncogene. Cell 1999;98: 295-303.
17. Chalmin F, Mignot G, Bruchard M et al. Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. Immunity 2012;36:362-373.
18. Yu H, Jove R. The STATs of cancer - New molecular targets come of age. Nat Rev Cancer 2004;4:97-105.
19. Li N, Grivennikov SI, Karin M. The unholy trinity: Inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell 2011;19:429-431.
20. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007;7:41-51.
21. Wang J, Sun Q, Morita Y et al. A differentiation checkpoint limits hematopoietic stem cell self-renewal in response to DNA damage. Cell 2012;148:1001-1014.
22. Chung YJ, Park BB, Kang YJ et al. Unique effects of Stat3 on the early phase of hematopoietic stem cell regeneration. Blood 2006; 108:1208-1215.
23. Lin L, Liu A, Peng Z et al. STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res 2011;71: 7226-7237.
24. Ho PL, Lay EJ, Jian W et al. Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer. Cancer Res 2012;72:3135-3142.
25. Guryanova OA, Wu Q, Cheng L et al. Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell 2011;19:498-511.
26. Su Y-J, Lai H-M, Chang Y-W et al. Direct reprogramming of stem cell properties in colon cancer cells by CD44. EMBO J 2011;30: 3186-3199.
27. Philp JA, Burdon TG, Watson CJ. Differential activation of STATs 3 and 5 during mammary gland development. FEBS Lett 1996;396:77-80.
28. Kunigal S, Lakka SS, Sodadasu PK et al. Stat3-siRNA induces Fas-mediated apoptosis in vitro and in vivo in breast cancer. Int J Oncol 2009;34:1209-1220.
29. Lee H, Zhang P, Herrmann A et al. Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. Proc Natl Acad Sci USA 2012;109:7765-7769.
30. Lavecchia A, Di Giovanni C, Novellino E. STAT-3 inhibitors: State of the art and new horizons for cancer treatment. Curr Med Chem 2011;18:2359-2375.
31. Wagner KU, Schmidt JW. The two faces of Janus kinases and their respective STATs in mammary gland development and cancer. J Carcinog 2011;10:32.
32. Su F, Ren F, Rong Y et al. Protein tyrosine phosphatase Meg2 dephosphorylates signal transducer and activator of transcription 3 and suppresses tumor growth in breast cancer. Breast Cancer Res 2012;14: R38.
33. Iliopoulos D, Hirsch HA, Wang G et al. Inducible formation of breast cancer stem cells and their dynamic equilibrium with nonstem cancer cells via IL6 secretion. Proc Natl Acad Sci USA 2011;108:1397-1402.
34. Zhou J, Wulfkuhle J, Zhang H et al. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci USA 2007;104:16158-16163.
35. Marotta LLC, Almendro V, Marusyk A et al. The JAK2/STAT3 signaling pathway is required for growth of CD441CD24-stem cell-like breast cancer cells in human tumors. J Clin Invest 2011;121:2723-2735.
36. Wagner BJ, Hayes TE, Hoban CJ et al. The SIF binding element confers sis/PDGF inducibility onto the c-fos promoter. EMBO J 1990;9:4477-4484.
37. Reya T, Duncan AW, Ailles L et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 2003;423:409-414.
38. Besser D, Bromberg JF, Darnell JE et al. A single amino acid substitution in the v-Eyk intracellular domain results in activation of Stat3 and enhances cellular transformation. Mol Cell Biol 1999;19:1401-1409.
39. Weber K, Bartsch U, Stocking C et al. A multicolor panel of novel lentiviral "gene ontology" (LeGO) vectors for functional gene analysis. Mol Ther 2008;16:698-706.
40. Welm BE, Dijkgraaf GJP, Bledau AS et al. Lentiviral transduction of mammary stem cells for analysis of gene function during development and cancer. Cell Stem Cell 2008;2:90-102.
41. Deome KB, Faulkin LJ, Jr., Bern HA et al. Development of mammary tumors from hyperplastic alveolar nodules transplanted into gland-free mammary fat pads of female C3H mice. Cancer Res 1959;19:515-520.
42. Dontu G, Abdallah WM, Foley JM et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003;17:1253-1270.
43. Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 2009;347:70-78.
44. Horvath CM, Wen Z, Darnell JE. A STAT protein domain that determines DNA sequence recognition suggests a novel DNAbinding domain. Genes Dev 1995;9:984-994.
45. Schust J, Berg T. A high-throughput fluorescence polarization assay for signal transducer and activator of transcription 3. Anal Biochem 2004;330:114-118.
46. Schust J, Sperl B, Hollis A et al. Stattic: A small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol 2006;13:1235-1242.
47. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-768.
48. Visvader Jane E, Lindeman Geoffrey J. Cancer stem cells: Current status and evolving complexities. Cell Stem Cell 2012;10:717-728.
49. Niwa H, Burdon T, Chambers I et al. Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3. Genes Dev 1998;12:2048-2060.
50. Prat A, Parker J, Karginova O et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010;12:R68.
51. Neve RM, Chin K, Fridlyand J et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-527.
52. Usary J, Zhao W, Darr D et al. Predicting drug responsiveness in human cancers using genetically engineered mice. Clin Cancer Res 2013;19:4889-4899.
53. Herschkowitz JI, Zhao W, Zhang M et al. Comparative oncogenomics identifies breast tumors enriched in functional tumorinitiating cells. Proc Natl Acad Sci USA 2012; 109:2778-2783.
54. Meyer MJ, Fleming JM, Ali MA et al. Dynamic regulation of CD24 and the invasive, CD44posCD24neg phenotype in breast cancer cell lines. Breast Cancer Res 2009;11:R82.
55. Fillmore C, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008;10:R25.
56. Sheridan C, Kishimoto H, Fuchs RK et al. CD441/CD242 breast cancer cells exhibit enhanced invasive properties: An early step necessary for metastasis. Breast Cancer Res 2006;8:R59.
57. Liu S, Ginestier C, Ou SJ et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res 2011;71:614-624.
58. Charafe-Jauffret E, Ginestier C, Iovino F et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009;69:1302-1313.
59. Ginestier C, Liu S, Diebel ME et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 2010;120:485-497.
60. Zhang X, Claerhout S, Prat A et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res 2013;73:4885-4897.
61. Ginestier C, Hur MH, Charafe-Jauffret E et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007;1:555-567.
62. Korkaya H, Kim GI, Davis A et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER21 breast cancer by expanding the cancer stem cell population. Mol Cell 2012;47:570-584.
63. Rokavec M, Wu W, Luo JL. IL6-mediated suppression of miR-200c directs constitutive activation of inflammatory signaling circuit driving transformation and tumorigenesis. Mol Cell 2012;45:777-789.